The remains of an Israeli F-16 that crashed after coming under Syrian fire. Photo: Jack Guez / AFP / Getty Images

Secretary of State Rex Tillerson's Middle East trip comes on the heels of Iranian escalation in the Syrian conflict that poses new security risks for Israel.

Tehran has long backed Syria’s president, Bashar al Assad, in no small part because he permits the Iranians a connection to Lebanon and transit for their support of Hezbollah. But Iran has now developed a military presence and infrastructure in Syria — not to defend Assad but to open a second front against Israel.

On Saturday, the Iranians sent a stealth, armed drone from a base it controls in Syria through Jordanian airspace and into Israel. After the Israelis intercepted the UAV and attacked the base from which it was launched and guided, Syrian air defense batteries opened fire and downed an Israeli F-16 over Israeli airspace. In response, Israel destroyed multiple SAM 5 and 17 batteries and radars in Syria.

Until now the U.S. has left Israel largely on its own when it comes to the growing Iranian presence in Syria. Russia may have turned the balance of power in Assad’s favor with its use of air power, but Putin would rather Russia help shape a ceasefire than get caught in an escalating war with the potential for casualties. 

The bottom line: In light of Iran's expanding presence in Syria — and the risks it's amplifying — Secretary Tillerson should add Israel to his itinerary to signal support and make clear that the U.S. will not stand on the sidelines if Iran’s interventions continue.

Dennis Ross is the William Davidson Distinguished Fellow and Counselor at the Washington Institute for Near East Policy and the author of “Doomed to Succeed: The U.S.-Israeli Relationship from Truman to Obama.”

Go deeper

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.

How the coronavirus pandemic could end

Illustration: Sarah Grillo/Axios

It's still the early days of the coronavirus pandemic, but history, biology and the knowledge gained from our first nine months with COVID-19 point to how the pandemic might end.

The big picture: Pandemics don't last forever. But when they end, it usually isn't because a virus disappears or is eliminated. Instead, they can settle into a population, becoming a constant background presence that occasionally flares up in local outbreaks.

Urban housing prices are on the rise

Data: ATTOM Data Solutions; Chart: Naema Ahmed/Axios

Home prices are rising rapidly across the U.S., according to ATTOM Data Solutions.

Driving the news: ATTOM released its 3Q 2020 figures this week, concluding that 77% of metro areas posted "double-digit annual home price gains." Profit margins rose in 86% of the 103 metropolitan statistical areas studied.